Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Prevalence and predictive value of anti-cyclic citrullinated protein antibodies for future development of rheumatoid arthritis in early undifferentiated arthritis.

Emad Y, Shehata M, Ragab Y, Saad A, Hamza H, Abou-Zeid A.

Mod Rheumatol. 2010 Aug;20(4):358-65. doi: 10.1007/s10165-010-0286-6. Epub 2010 Apr 3.

PMID:
20364358
3.

Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.

van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.

Arthritis Rheum. 2009 Aug;60(8):2232-41. doi: 10.1002/art.24716.

4.

Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.

Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapää-Dahlqvist S.

Ann Rheum Dis. 2006 Apr;65(4):453-8. Epub 2005 Sep 21.

5.

Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset.

Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Ménard HA, Zhou ZJ, Palosuo T, Van Venrooij WJ, Wilder RL, Klippel JH, Schumacher HR Jr, El-Gabalawy HS.

Arthritis Res. 2000;2(3):236-43. Epub 2000 Mar 31.

6.

Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.

Chang PY, Yang CT, Cheng CH, Yu KH.

Int J Rheum Dis. 2016 Sep;19(9):880-6. doi: 10.1111/1756-185X.12552. Epub 2015 May 4.

PMID:
25940989
7.

Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis.

Ateş A, Karaaslan Y, Aksaray S.

Clin Rheumatol. 2007 Apr;26(4):499-504. Epub 2006 May 3.

PMID:
16670828
8.

Anti-cyclic citrullinated peptide antibodies--activity markers in rheumatoid arthritis.

Predeteanu D, Varzaru L, Balanescu A, Bojinca V, Opris D, Vlad V, Berghea F, Abobului M, Constantinescu C, Ionescu R.

J Med Life. 2009 Jan-Mar;2(1):36-41.

9.

Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?

Girelli F, Foschi FG, Bedeschi E, Calderoni V, Stefanini GF, Martinelli MG.

Eur Ann Allergy Clin Immunol. 2004 Apr;36(4):127-30.

PMID:
15180353
10.

Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.

Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H, Sugii S, Ozawa Y, Tohma S.

J Rheumatol. 2006 Dec;33(12):2390-7. Epub 2006 Aug 15.

PMID:
16924694
11.

The association of anti-CCP antibodies with disease activity in rheumatoid arthritis.

Serdaroğlu M, Cakirbay H, Değer O, Cengiz S, Kul S.

Rheumatol Int. 2008 Aug;28(10):965-70. doi: 10.1007/s00296-008-0570-3. Epub 2008 Apr 17.

12.

Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in Iranian patients with rheumatoid arthritis: evaluation of clinical value and association with disease activity.

Shakiba Y, Koopah S, Jamshidi AR, Amirzargar AA, Massoud A, Kiani A, Nicknam MH, Nazari B, Nikbin B.

Iran J Allergy Asthma Immunol. 2014 Jun;13(3):147-56.

13.

Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.

Maraina CH, Nurdayana AK, Rusni D, Azwany Y.

Int J Rheum Dis. 2010 Oct;13(4):335-9. doi: 10.1111/j.1756-185X.2010.01552.x.

PMID:
21199468
14.

Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).

Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B; BARFOT Study Group..

Ann Rheum Dis. 2004 Sep;63(9):1090-5.

15.

The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus.

Popescu C, Zofotă S, Bojincă V, Ionescu R.

Rom J Intern Med. 2013 Jul-Dec;51(3-4):179-87.

PMID:
24620631
16.

Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis.

Krol A, Garred P, Heegaard NH, Christensen AF, Hetland ML, Stengaard-Pedersen K, Junker P, Madsen HO, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Pedersen JK, Svendsen AJ, Tarp U, Pødenphant J, Lindegaard H, Østergaard M, Hørslev-Petersen K, Jacobsen S.

Scand J Rheumatol. 2015;44(1):8-12. doi: 10.3109/03009742.2014.918651. Epub 2014 Sep 10.

PMID:
25205362
17.

Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis.

Lee DM, Phillips R, Hagan EM, Chibnik LB, Costenbader KH, Schur PH.

Ann Rheum Dis. 2009 Feb;68(2):201-8. doi: 10.1136/ard.2007.084509. Epub 2008 Apr 7.

PMID:
18390910
18.

The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ.

Arthritis Rheum. 2000 Jan;43(1):155-63.

20.

Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.

De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, De Keyser F.

Ann Rheum Dis. 2005 Feb;64(2):299-302. Epub 2004 May 27.

Supplemental Content

Support Center